VivoSeq
Cardiovascular

Essential Thrombocythemia

42

Pipeline Programs↗

10

Active Trials↗

21

Companies Involved↗

Essential Thrombocythemia is a moderately active landscape with 42 programs across 21 companies. The most active players are Ajax Therapeutics, Inc., Eli Lilly, AstraZeneca. 4 therapies are approved with 17 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

58/100

Pipeline Velocity

0/100

Mech. Concentration

7/100

Completion Rate

76/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Ajax Therapeutics, Inc.

1 program

Phase 1Eli Lilly logo

Eli Lilly

1 program

Phase 1AstraZeneca logo

AstraZeneca

1 program

Phase 1R

RECORDATI GROUP

1 program

Phase 1GSK logo

GSK

2 programs

Phase 2K

Kartos Therapeutics, Inc.

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

88%

Small molecule

37 of 42 classified programs — the dominant modality here.

12%ALL OTHERSMonoclonal antibody410%RNA therapy12%

Small molecule leads; the ring shows all 42 classified programs, each share of the total. Modality classified for 96% of 45 pipeline programs.

Analysis

Trial Status

50

clinical trials

Completed28 · 56%
Terminated7 · 14%
Active, not recruiting6 · 12%
Recruiting4 · 8%
Unknown status3 · 6%
Withdrawn2 · 4%

Clinical Trials

Trial Activity

50 trials

Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Childhood and Adolescent Essential Thrombocythemia
Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT04226950·40 enrolled
A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
Recruiting·AAjax Therapeutics, Inc.·Phase 1·NCT06343805·76 enrolled
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Recruiting·SSwedish Orphan Biovitrum·Phase 3·NCT03165734·399 enrolled
A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study to Evaluate the Efficacy and Safety of Bomedemstat (MK-3543) Versus Hydroxyurea in Cytoreductive Therapy Naïve Essential Thrombocythemia Participants
Recruiting·Merck & Co. logoMerck & Co.·Phase 3·NCT06456346·300 enrolled
The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia
Active, not recruiting·RRWTH Aachen University·Phase 2·NCT02577926·207 enrolled
Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2
Active, not recruiting·TThe University of Texas Health Science Center at San Antonio·Phase 2·NCT04081220·9 enrolled
Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance
Active, not recruiting·PPharmaEssentia·Phase 3·NCT04285086·174 enrolled
A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
Active, not recruiting·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 1/2·NCT04446650·31 enrolled
IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)
Active, not recruiting·—·Phase 2·NCT04262141·4 enrolled
A Phase 3, Randomized, Open-label, Active-Comparator-Controlled Clinical Study to Evaluate the Safety and Efficacy of Bomedemstat (MK-3543/IMG-7289) Versus Best Available Therapy (BAT) in Participants With Essential Thrombocythemia Who Have an Inadequate Response to or Are Intolerant of Hydroxyurea
Active, not recruiting·Merck & Co. logoMerck & Co.·Phase 3·NCT06079879·340 enrolled
Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera
Completed·GGeron Corporation·Phase 2·NCT01243073·20 enrolled
Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib
Completed·CCTI BioPharma·Phase 2·NCT04884191·165 enrolled
Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 2·NCT01692366·8 enrolled
Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 2·NCT01420783·81 enrolled
A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis
Completed·Novartis logoNovartis·Phase 3·NCT02087059·51 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)